Jul 5, 2024, 01:49
Highlights of the RADIOSA phase II trial presented at ESTRO24
European Society for Radiotherapy and Oncology (ESTRO) shared a paper on LinkedIn:
“Highlights of the RADIOSA phase II trial presented at ESTRO24: SBRT + short-term ADT significantly improves outcomes in oligorecurrent hormone-sensitive prostate cancer patients.
Report by Simon Spohn.”
Read further.
Source: ESTRO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19